SCHEMBL4020320

SCHEMBL4020320

CC(C)c1ccc(C(=O)O)c(CCCCN2CCC(OCc3ccccc3)CC2)c1

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
BCHE P06276 12/20 0.66
TMEM97 Q5BJF2 1/20 0.47
CARM1 Q86X55 1/20 0.47
PRMT6 Q96LA8 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
PRMT8 Q9NR22 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAOB P27338 6/20 0.44
MAOA P21397 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4023303 0.86 BCHE (0.65) BCHEHRH3MEN1KMT2A
SCHEMBL4022974 0.85 BCHE (0.64) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL4029991 0.85 BCHE (0.64) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL4021849 0.85 BCHE (0.65) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL4023934 0.82 BCHE (0.67) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL4027465 0.80 BCHE (1.00) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL4023211 0.78 BCHE (0.63) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL4024108 0.78 BCHE (0.63) BCHETMEM97CARM1PRMT6SIGMAR1
SCHEMBL4020617 0.78 BCHE (0.57) BCHETMEM97CARM1PRMT6SIGMAR1
Oxalic Acid SCHEMBL7316888 0.74 BCHE (0.66) BCHETMEM97CARM1PRMT6SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446400-B1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO LTD (KR) 2009-01-28 EP claimed
US-7288552-B2 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2007-10-30 US claimed
EP-1446400-A4 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO LTD (KR) 2005-06-01 EP claimed
US-20050043316-A1 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO., LTD. (KR) 2005-02-24 US claimed
EP-1446400-A1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC Nara Co. Ltd. (KR) 2004-08-18 EP claimed
WO-2003033489-A1 PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME STC NARA CO., LTD. (KR) 2003-04-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043316-A1 Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same APP, ACHE, PSEN1 BCHE 7/4885TMEM97 1837/4885CARM1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.